Hepatic ARID3A facilitates liver cancer malignancy by cooperating with CEP131 to regulate an embryonic stem cell-like gene signature

Cell Death Dis. 2022 Aug 25;13(8):732. doi: 10.1038/s41419-022-05187-9.

Abstract

Liver cancer stemness refers to the stem cell-like phenotype of hepatocarcinoma cells and is closely related to a high degree of tumour malignancy. Here, we identified AT-rich interacting domain 3A (ARID3A) as one of the most upregulated stemness-related transcription factors in liver cancer by an in vitro functional screen. ARID3A can promote liver cancer cell viability and metastasis both in vitro and in vivo. Mechanistically, ARID3A interacts with CEP131 and transcriptionally activates KDM3A by co-occupying its promoter element, further upregulating the expression of downstream embryonic stem (ES) signature genes via demethylation of H3K9me2. ARID3A and CEP131 promote an ES cell gene signature through activation of KDM3A and contribute to the poor prognosis of liver cancer patients. Collectively, these results provide evidence highlighting a transcription-dependent mechanism of ARID3A in stemness regulation in liver cancer. The ARID3A/CEP131-KDM3A regulatory circuit could serve as a prognostic indicator and potential therapeutic target for liver cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle Proteins / metabolism*
  • Cytoskeletal Proteins / metabolism*
  • DNA-Binding Proteins* / genetics
  • DNA-Binding Proteins* / metabolism
  • Embryonic Stem Cells / metabolism
  • Humans
  • Jumonji Domain-Containing Histone Demethylases / metabolism
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / metabolism
  • Promoter Regions, Genetic / genetics
  • Transcription Factors / metabolism*

Substances

  • ARID3A protein, human
  • CEP131 protein, human
  • Cell Cycle Proteins
  • Cytoskeletal Proteins
  • DNA-Binding Proteins
  • Transcription Factors
  • Jumonji Domain-Containing Histone Demethylases
  • KDM3A protein, human